Seismic Therapeutic Obtains Total of $222 for Immunology Platform

Seismic Therapeutic has successfully obtained just over $120 through a second funding stage, aiming to expand its immunology platform. With this recent funding, the pharmaceutical business has raised $222 million in total. 

The funding phase was led by new investor Bessemer Venture Partners, along with other newcomers like Codon Capital, Alexandria Venture Investments and Amgen Ventures Codon Capital. 

The company will use the funds to move forward with the initial testing of its main treatments, S-1117 and S-4321. 

S-1117 is used to treat diseases caused by the body’s own antibodies, both in the short and long term. On the other hand, S-4321 is a drug that boosts the activity of PD-1, a regulator on immune cells called T-cells. 

Jo Viney, head executive of Seismic Therapeutic, commented, “We are delighted to secure the support of such a strong syndicate of investors who believe in Seismic’s ability to pioneer a new era of immunology drug development integrating machine learning.” 

Viney went on to add, “We believe the time is right to harness advances in machine learning to discover the next generation of biologics drugs to improve the lives of patients with autoimmune disease.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.